ClinicalTrials.gg
TerminatedNCT03860155Updated Nov 17, 2021

Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

A Phase 1/2 interventional study of allo-APZ2-ACLF in Acute-On-Chronic Liver Failure, sponsored by RHEACELL GmbH & Co. KG. Terminated at 5 sites in Germany. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by RHEACELL GmbH & Co. KG · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Very slow recruitment of patients and the current COVID-19 pandemic situation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Acute-On-Chronic Liver Failure with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Germany.

Started
2019
with 1 other
Phase 1/2
Only one
of the 16
Registered
6th of 16
by date

Among the 16 studies in Acute-On-Chronic Liver Failure with a site in Germany, this one is one of 2 that started in 2019, is the only one in phase 1/2, and was the 6th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

6 of the 16 studies in Acute-On-Chronic Liver Failure with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Acute-On-Chronic Liver Failure with a site in Germany, or all of them as a file.
02

Study summary

This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v. doses of the investigational medicinal product (IMP) allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF). The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

Read the detailed description

This is an interventional, phase I/IIa clinical trial to investigate the efficacy (by changes in Model for End-Stage Liver Disease [MELD] score) and safety (by monitoring adverse events) of the IMP in patients with acute-on-chronic liver failure grade 2 and 3. The allogeneic IMP allo-APZ2-ACLF contains skin-derived ABCB5-positive mesenchymal stem cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

The clinical trial will be conducted in Germany and will consist of a screening, treatment and efficacy follow-up period, and a safety follow-up period.The total duration is planned to be about 3 years including the follow-up period.

The planned sample size is up to 18 treated patients. 2 x 10e6 cells/kg, each at Day 0, Day 5 (±1) and Day 13 (±1), will be administrated into peripheral vein (arm) by use of a perfusor. allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in HRG-solution. In patients which require dialysis, the IMP application has to be performed at least 3 hours after end of dialysis. This is necessary to ensure that cells and secreted molecules are not cleared from the system by the dialysis.

Patients will be followed up for 24 weeks with clinic visits at Weeks 3, 4, 8, 12, 16, 20 and 24 after IMP application. Further safety follow-ups will be scheduled as home interviews via telephone at Months 15 and 24. If necessary (at the discretion of the investigator), safety follow-ups at Months 15 and 24 can also be carried out as an on-site visit.

The first six patients will be enrolled into the clinical trial consecutively with an interval of 2 weeks between the third IMP-application of the first patient and the enrolment of the second patient, etc. During this period the patient receives all three applications and immediate severe adverse effects (allergic reactions, SIRS) that could occur after treatment would be reported before treatment start of the next patient.

The safety data of these first six patients will be reviewed by the Medical Monitor continuously, if required with assistance of the further members of the DSMB. The safety evaluation of the DSMB will be submitted to the PEI and recruitment can only be continued after approval of an amendment.

03

Conditions studied

  • Acute-On-Chronic Liver Failure

Keywords

  • Acute-on-Chronic Liver Failure
  • ACLF
  • ABCB5
  • ATP Binding Cassette Subfamily B Member 5
  • allogeneic
  • mesenchymal stem cells
  • advanced therapy medicinal product
  • somatic cell therapy
  • phase I/IIa
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients, aged 20 to 75 years;
  2. Diagnosed ACLF of grade 2 or 3 according to EASL-CLIF definition;
  3. Patients are not eligible for liver transplant (confirmed by transplantation board);
  4. Histology result of liver not older than 4 weeks before screening;
  5. Women of must have a negative blood pregnancy test at screening;
  6. Women of childbearing potential and fertile men, and their partners must be willing to use highly effective methods during the course of the clinical trial;
  7. Written from patient, legal or authorized representative or a confirmation of justification of trial participation by an independent medical consultant. In case of confirmation by the independent medical consultant, a deferred informed consent from patient, legal or authorized representative has to be given.

Exclusion criteria

Exclusion Criteria:

  1. Patients without cirrhosis;
  2. Patients with ACLF grade 1 according to EASL-CLIF definition;
  3. Patient with septic shock;
  4. Patients with known hepatopulmonal syndrome (HPS);
  5. Patients with known pulmonary embolism that needs anticoagulative treatment;
  6. Patients with pre-existing lung disease with necessity of respiratory support;
  7. Active or history of malignancy within 5 years prior to trial entry;
  8. Known infection with (HIV˗1, HIV-2);
  9. Any known allergies to components of the IMP;
  10. Current or previous (within 30 days of enrolment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
  11. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
  12. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
  13. Pregnant or nursing women;
  14. Employees of the sponsor, or employees or relatives of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    allo-APZ2-ACLF

    Application of IMP into peripheral vein (arm) by use of a perfusor.

    Biological: allo-APZ2-ACLF

Interventions

  • Biologicalallo-APZ2-ACLF

    Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.

    Also known as: Skin-derived ABCB5-positive mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Change of Model for End-Stage Liver Disease (MELD) score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.

    Model for End-Stage Liver Disease (MELD) score for assessing the severity of chronic liver disease is measured as absolute change to baseline score at Week 24 or last available post-baseline measurement if the Week 24 score is missing.

    Time frame: Week 24, or last available post-baseline measurement of Days 5 (±1) or 13 (±1) or Weeks 3, 4, 8, 12, 16 or 20 if the Week 24 measurement is missing [LOCF].

  2. Assessment of adverse event (AE) occurrence

    All AEs occurring during the clinical trial will be registered, documented and evaluated.

    Time frame: Between Screening and Month 24

Secondary outcomes

  1. Change of MELD score at Weeks 3, 4, 8, 12, 16 and 20

    Model for End-Stage Liver Disease score is measured as absolute change to baseline score.

    Time frame: Weeks 3, 4, 8, 12, 16 and 20

  2. Change of Child-Pugh-Score at Weeks 3, 4, 8, 12, 16, 20 and 24

    Child-Pugh-Score to assess the prognosis of chronic liver disease and cirrhosis is measured as absolute change to baseline score.

    Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24

  3. Change of CLIF-C ACLF score at Weeks 3, 4, 8, 12, 16, 20 and 24

    CLIF-C ACLF score to assess the mortality in Acute-on-chronic liver failure patients is measured as absolute change to baseline score.

    Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24

  4. Overall survival time until Week 24

    Assessment of overall survival time.

    Time frame: Between Screening and Week 24

  5. Complications of ACLF (hepatorenal syndrome [HRS], variceal bleeding, ascites, hepatic encephalopathy [HE], spontaneous bacterial peritonitis [SBP])

    Assessment, documentation and evaluattion of ACLF related complications (hepatorenal syndrome, variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis).

    Time frame: Between Screening and Week 24

  6. Transient elastography assessment at Weeks 4, 12 and 24

    Mapping of the elastic properties and the stiffness of the tissue as assessed by transient elastography imaging

    Time frame: Weeks 4, 12 and 24

  7. Infections (proven infection necessitating systemic use of antibiotics)

    All infections occurring during the clinical trial will be registered, documented and evaluated.

    Time frame: Between Screening and Month 24

  8. Change of levels of C-reactive protein in serum at Weeks 3, 4, 8, 12, 16, 20 and 24

    C-reactive protein levels in the serum will be measured.

    Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24

  9. Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24

    The following laboratory variables will be measured and evaluated: Albumin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).

    Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24

  10. Changes in the profile of 80 different immunomodulatory cytokines at Weeks 3, 4, 8, 12, 16, 20 and 24

    Fluorescence based analysis of 80 different immunomodulatory cytokine parameters in the patient's serum samples as assessed by a 80plex Human Cytokine Antibody Array Kit.

    Time frame: Weeks 3, 4, 8, 12, 16, 20 and 24

  11. Changes in dialytic treatment until Week 24

    For patients with dialysis prior to Screening: Time to first dialysis after first IMP administration and time to last dialysis after first IMP administration until Week 24 will be assessed. For patients with no dialytic treatment prior to Screening the overall diaylsis timespan from first dialysis after first IMP administration until last dialysis will be measured.

    Time frame: Between Screening and Week 24

  12. Time to respiratory failure after first IMP administration until Week 24

    Timespan to respiratory failure after first IMP administration until Week 24 will be measured.

    Time frame: Between Day 0 (after first IMP administration) and Week 24

  13. Duration of the initial hospital stay

    Initial hospitalisation time will be evaluated.

    Time frame: Between Screening and Week 24

  14. Duration of initial intensive care stay

    The duration of initial intensive care stay will be evaluated.

    Time frame: Between Screening and Week 24

  15. Optional: Evaluation of liver biopsy (necrosis quantification)

    Extent of necrosis will be quantified by the pathologist of the clinical trial center.

    Time frame: Between Week 8 and Week 24

  16. Physical examination at Week 24

    A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.

    Time frame: Week 24

  17. Vital signs at Week 24: Body temperature

    Body temperature will be measured.

    Time frame: Week 24

  18. Vital signs at Week 24: Blood pressure

    Blood pressure will be measured.

    Time frame: Week 24

  19. Vital signs at Week 24: Heart rate

    Heart rate will be measured.

    Time frame: Week 24

  20. Vital signs at Week 24: Respiratory rate

    Respiratory rate will be measured.

    Time frame: Week 24

  21. Hematological laboratory parameters at Week 24

    The hematological laboratory values for "hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, platelet count" will be measured.

    Time frame: Week 24

  22. Clinical chemistry parameters at Week 24

    The clinical chemistry values for "sodium, potassium, calcium, urea, creatinine, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, CRP" will be measured.

    Time frame: Week 24

  23. Coagulation parameter "factor V" at Week 24

    The coagulation value for "factor V" will be measured.

    Time frame: Week 24

  24. Coagulation parameter "INR" at Week 24

    The coagulation value for "INR" will be measured.

    Time frame: Week 24

  25. Overall survival at Week 24 and at Month 24

    Overall survival at Week 24 and at Month 24 will be evaluated.

    Time frame: Week 24, Month 24

07

Study locations

5 sites
  • Universitätsklinikum Carl-Gustav-Carus an der TU Dresden, Medizinische Klinik I
    Dresden, 01307, Germany
  • Universitätsklinikum Essen, Klinik für Gastroenterologie und Hepatologie, Medizinisches Forschungszentrum
    Essen, 45147, Germany
  • Universitätsklinikum Frankfurt, Medizinische Klinik 1, Sektion Translationale Hepatologie
    Frankfurt, 60590, Germany
  • Universitätsklinikum Magdeburg A.ö.R., Medizinische Fakultät der Otto-von-Guericke-Universität
    Magdeburg, 39120, Germany
  • Medizinische Fakultät Mannheim der Universität Heidelberg, II. Medizinische Klinik
    Mannheim, 68167, Germany
08

References and documents

Publications

  • Kerstan A, Niebergall-Roth E, Esterlechner J, Schroder HM, Gasser M, Waaga-Gasser AM, Goebeler M, Rak K, Schrufer P, Endres S, Hagenbusch P, Kraft K, Dieter K, Ballikaya S, Stemler N, Sadeghi S, Tappenbeck N, Murphy GF, Orgill DP, Frank NY, Ganss C, Scharffetter-Kochanek K, Frank MH, Kluth MA. Ex vivo-expanded highly pure ABCB5+ mesenchymal stromal cells as Good Manufacturing Practice-compliant autologous advanced therapy medicinal product for clinical use: process validation and first in-human data. Cytotherapy. 2021 Feb;23(2):165-175. doi: 10.1016/j.jcyt.2020.08.012. Epub 2020 Oct 1. PubMed 33011075 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Mar 2021, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2019
First posted
Mar 1, 2019
StartActual
Mar 22, 2019
Primary completionActual
Mar 26, 2021
CompletionActual
Mar 26, 2021
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03860155
Lead sponsor
RHEACELL GmbH & Co. KG
Collaborators
FGK Clinical Research GmbH, Ticeba GmbH
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
Mar 22, 2019
Primary completion
Mar 26, 2021
Completion
Mar 26, 2021
Last update
Nov 17, 2021

Study contacts

Matthias Ebert, Prof. Dr.
principal investigator · Med. Fakultät Mannheim der Universität Heidelberg, II. Med. Klinik, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion